Clinical trials: B Lymphoblastic Leukemia, active
Chronic Lymphocytic Leukemia (CLL), Splenic Marginal Zone Lymphoma
Innovative 3D Preclinical Models for Mature B-cell Malignancies to Advance Personalized Immuno and Combination Therapies
Adult patients with chronic lymphocytic leukemia (CLL), splenic marginal-zone lymphoma (SMZL) and hairy cell leukemia (HCL) followed at participating clinical sites will be enrolled and undergo sampling of additional amount of…
- Conditions
- Chronic Lymphocytic Leukemia (CLL), Splenic Marginal Zone Lymphoma, Hairy Cell Leukemia (HCL)
- Trial name
- IMPACT (NCT07759661)
- Where
- Italy
- Volunteers
- 64 people
- Sponsor
- IRCCS San Raffaele
Hematologic Diseases, Chronic Myeloid Leukemia
Muscle Dysfunction in Patients With Hematological Diseases Referred to Stem Cell Transplant
PURPOSE: To investigate the effect of the disease and HSCT on muscle dysfunction and to investigate the prognostic role of muscle dysfunction at critical decision points in patients with hematological diseases referred to…
- Conditions
- Hematologic Diseases, Chronic Myeloid Leukemia, Acute Myeloid Leukemia, Acute Lymphoid Leukemia
- Trial name
- NCT04167683
- Testing
- No intervention
- Where
- Denmark
- Volunteers
- 144 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Cancer, Chronic Lymphocytic Leukemia
Time Restricted Eating in Haematological Malignancies
The goal of this clinical trial is to learn if time restricted eating (TRE), a form of intermittent fasting, can impact health outcomes in patients with chronic lymphocytic leukemia (CLL).
- Trial name
- NCT06862323
- Testing
- Time-Restricted Eating
- Where
- Canada
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- British Columbia Cancer Agency
B-ALL
Bispecific CD19/CD22 CAR-T for Treatment of Children and Young Adults With r/r B-ALL
The purpose of this study is to evaluate the safety and efficiency of autologous CD19/CD22 CAR-T lymphocytes in a cohort of pediatric and young adult patients with relapsed /refractory B-lineage acute lymphoblastic leukemia
- Trial name
- NCT04499573
- Testing
- CD19/CD22 CAR-T
- Where
- Russia
- Volunteers
- 50 people
- Sponsor
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
This phase II trial tests the safety, side effects and how well giving tafasitamab with acalabrutinib and venetoclax works for the treatment of chronic lymphocytic leukemia (CLL)/small cell lymphoma (SLL).
- Conditions
- Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Small Lymphocytic Lymphoma
- Trial name
- NCT07582159
- Testing
- Acalabrutinib, Biospecimen Collection, Bone Marrow Biopsy
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- City of Hope Medical Center
Chronic Lymphocytic Leukemia
Description of the Immune Deficiency in Patients With Untreated Chronic Lymphocytic Leukemia and Search for Predictive Factors of Infectious Risk
Chronic Lymphocytic Leukemia (CLL) is the most common adult leukemia in western countries. CLL is most often discovered incidentally when a blood test carried out for another reason highlights an increase of subpopulation of…
- Trial name
- NCT06475469
- Testing
- Blood sampling & Chest CT without injection
- Where
- France
- Volunteers
- 75 people
- Sponsor
- CHU de Reims
Richter Syndrome
A Trial of CHOP-R Therapy, With or Without Acalabrutinib, in Patients With Newly Diagnosed Richter's Syndrome
The STELLAR trial will assess the effect of acalabrutinib taken in combination with CHOP-R compared to taking CHOP-R alone in patients with newly diagnosed Richter's Syndrome (RS).
- Trial name
- STELLAR (NCT03899337)
- Testing
- Acalabrutinib, Cyclophosphamide, Doxorubicin
- Where
- 17 sites in United Kingdom
- Volunteers
- 72 people
- Sponsor
- University of Birmingham
Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell
A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
The purpose of this study is to characterize safety and to determine the putative recommended Phase 2 dose(s) (RP2D[s]), optimal dosing schedule(s) and route(s) of administration of JNJ-80948543 in Part A (Dose Escalation) and to…
- Trial name
- NCT05424822
- Testing
- JNJ-80948543
- Where
- 29 sites in United States, Australia and 6 more
- Volunteers
- 167 people
- Sponsor
- Janssen Research & Development, LLC
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Ann Arbor Stage I Lymphoma, Ann Arbor Stage II Lymphoma
- Trial name
- NCT05334069
- Testing
- Questionnaire Administration, Biospecimen Collection
- Where
- 751 sites in United States
- Volunteers
- 2,900 people, healthy volunteers welcome
- Sponsor
- Alliance for Clinical Trials in Oncology
Recurrent B Acute Lymphoblastic Leukemia
Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia
This randomized phase III trial studies how well blinatumomab works compared with standard combination chemotherapy in treating patients with B-cell acute lymphoblastic leukemia that has returned after a period of improvement…
- Trial name
- NCT02101853
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Asparaginase, Blinatumomab
- Where
- 186 sites in United States, Australia and 3 more
- Volunteers
- 669 people
- Sponsor
- National Cancer Institute (NCI)
CD19 Positive, CD20 Positive
Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia
This phase I trial studies the side effects and best dose of CD19/CD20 chimeric antigen receptor (CAR) T-cells when given together with chemotherapy, and to see how effective they are in treating patients with non-Hodgkin's…
- Conditions
- CD19 Positive, CD20 Positive, Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma
- Trial name
- NCT04007029
- Testing
- Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Fludarabine Phosphate
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Phase I: Relapsed or Refractory B-cell Malignancies, Phase II Cohort A: Relapsed or Refractory Mantle Cell Lymphoma
Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies
This is an open-label, two-part study to assess the safety, tolerability, pharmacokinetics and clinical efficacy of acalabrutinib in Chinese adult subjects with R/R MCL, CLL and other B-cell malignancies.
- Conditions
- Phase I: Relapsed or Refractory B-cell Malignancies, Phase II Cohort A: Relapsed or Refractory Mantle Cell Lymphoma, Phase II Cohort B: Relapsed or Refractory Chronic Lymphocytic Leukemia
- Trial name
- NCT03932331
- Testing
- Acalabrutinib
- Where
- 23 sites in China
- Volunteers
- 105 people
- Sponsor
- AstraZeneca
Hematologic Malignancy, AML
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Tagraxofusp is a protein-drug conjugate consisting of a diphtheria toxin redirected to target CD123 has been approved for treatment in pediatric and adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN).
- Conditions
- Hematologic Malignancy, AML, ALL, BPDCN
- Trial name
- NCT05476770
- Testing
- Tagraxofusp, Fludarabine, Cytarabine
- Where
- 31 sites in United States, Australia
- Volunteers
- 54 people
- Sponsor
- Therapeutic Advances in Childhood Leukemia Consortium
Non-Hodgkin Lymphoma
A Rollover Study of CC-122
The purpose of the study is to provide CC-122 treatment to participants who have been receiving treatment in other CC-122 clinical trials investigating CC-122 for more than 5 years (CC-122-ST-001 [NCT01421524], CC-122-ST-002…
- Trial name
- NCT05688475
- Testing
- CC-122, Dexamethasone
- Where
- 7 sites in United States, France and 2 more
- Volunteers
- 12 people
- Sponsor
- Bristol-Myers Squibb
Acute Leukemia, Myelodysplastic Syndrome
Study of QUAIL-100 in Pediatric and Young Adult Participants With High-Risk Hematologic Malignancies Who Have Received a Hematopoietic Stem Cell Transplantation
Study of QUAIL-100 in Patients With High Risk Acute Leukemia and Myelodysplastic Syndrome Who Have Received Hematopoietic Stem Cell Transplant
- Trial name
- NCT07573111
- Testing
- QUAIL-100
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Laguna Biotherapeutics, Inc.
Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
This phase II trial studies how well inotuzumab ozogamicin works in treating younger patients with B-lymphoblastic lymphoma or CD22 positive B acute lymphoblastic leukemia that has come back (relapsed) or does not respond to…
- Conditions
- Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma, Refractory B Acute Lymphoblastic Leukemia, Refractory B Lymphoblastic Lymphoma
- Trial name
- NCT02981628
- Testing
- Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Aspiration and Biopsy
- Where
- 157 sites in United States, Puerto Rico
- Volunteers
- 80 people
- Sponsor
- Children's Oncology Group
B Acute Lymphoblastic Leukemia, B-Non Hodgkin Lymphoma
JY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ Leukemia
This study is an investigator-initiated single center, single arm clinical study with a target population of patients with relapsed or refractory B cell lymphoma / leukemia.
- Trial name
- NCT06940960
- Testing
- JY231 Injection
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Affiliated Hospital of Guangdong Medical University
Burkitt Lymphoma, Lymphoblastic Lymphoma, Adult
Thiotepa, Cyclophosphamide, Clarithromycin and Cytarabine
This study is an observational study on the efficacy and safety of auto-HSCT in adult patients with Burkitt lymphoma, lymphoblastic lymphoma, and acute lymphoblastic leukemia who received TCCA conditioning regimen.
- Conditions
- Burkitt Lymphoma, Lymphoblastic Lymphoma, Adult, Acute Lymphoblastic Leukemia, Adult
- Trial name
- TCCA (NCT06060782)
- Testing
- Thiotepa, cyclophosphamide, cladribine, and cytarabine conditioning regimen
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Fifth Affiliated Hospital, Sun Yat-Sen University
B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Asciminib as Maintenance Treatment After Cellular Therapies for Adults With Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
This phase I trial tests the safety, side effects and best dose of asciminib as maintenance treatment for adults with Philadelphia chromosome positive acute lymphoblastic leukemia (ALL) who have undergone cellular therapies such…
- Trial name
- NCT07040982
- Testing
- Asciminib, Biospecimen Collection, Bone Marrow Aspiration
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- City of Hope Medical Center
Chronic Lymphocytic Leukemia
A Study of Clinical Outcomes in Chronic Lymphocytic Leukemia (CLL) Patients Treated With Venetoclax in Greece
This study is being done to evaluate the clinical outcomes of Chronic Lymphocytic Leukemia (CLL) participants treated with venetoclax as routine standard of care in Greece.
- Trial name
- NCT04159779
- Where
- 21 sites in Greece
- Volunteers
- 180 people
- Sponsor
- AbbVie